Another day, another record low., page-5

It’s incredible that so much ‘air-time’ on these threads is taken up with ridiculous circular arguments about the Viraleze post-market trial.

Viraleze as far as I’m concerned as been a commercial flop and a money pit for the company. IMO the product is non-core and has proven to be a massive distraction for the company for almost 4 years, rather than focusing on DEP and bringing new DEP drugs into the clinic.

The share price has fallen from $2.50 to 12.5 cents for a reason, with more share price pressure likely. It’s like all the disciples, pom-pom clubbers and late-to-the-party Viralezers are on the Titanic, but are oblivious to the sinking because they are too busy arguing as to whether the soup at dinner was intentionally salty.